Cargando…

PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma

BACKGROUND: Sarcomas represent 10%–15% of cancers in adolescent and young adult (AYA) patients, and survival for those with metastatic disease or relapse is poor. Immunotherapy with checkpoint inhibition has improved outcomes in multiple tumor types, but data in advanced sarcomas, particularly withi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheinberg, Tahlia, Lomax, Anna, Tattersall, Martin, Thomas, David, McCowage, Geoff, Sullivan, Michael, Karim, Rooshdiya, Luk, Peter P., Mahar, Annabelle, Bonar, Fiona, Bhadri, Vivek A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451371/ https://www.ncbi.nlm.nih.gov/pubmed/33314769 http://dx.doi.org/10.1002/cnr2.1327

Ejemplares similares

Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma
por: McCaughan, Georgia J. B., et al.
Publicado: (2016)

Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes
por: Vargas, Ana Cristina, et al.
Publicado: (2020)

Systemic treatments and outcomes in CIC ‐rearranged Sarcoma: A national multi‐centre clinicopathological series and literature review
por: Connolly, Elizabeth A., et al.
Publicado: (2022)

Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma
por: Liu, Jiayong, et al.
Publicado: (2021)

Genome wide methylation profiling of selected matched soft tissue sarcomas identifies methylation changes in metastatic and recurrent disease
por: Vargas, Ana Cristina, et al.
Publicado: (2021)

NFB-18. IMMUNE FUNCTION IN CHILDREN TREATED WITH TRAMETINIB
por: Moukhaiber, Perla, et al.
Publicado: (2020)

Mesenchymal chondrosarcoma: An Australian multi‐centre cohort study
por: Strach, Madeleine C., et al.
Publicado: (2022)

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
por: Judson, Ian, et al.
Publicado: (2019)

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
por: Que, Yi, et al.
Publicado: (2021)

Recent advances and application of PD-1 blockade in sarcoma
por: Zuo, Wenli, et al.
Publicado: (2019)

Psychosocial Assessment Using Telehealth in Adolescents and Young Adults With Cancer: A Partially Randomized Patient Preference Pilot Study
por: Chalmers, John Alexander, et al.
Publicado: (2018)

Ub-ISAP: a streamlined UNIX pipeline for mining unique viral vector integration sites from next generation sequencing data
por: Kamboj, Atul, et al.
Publicado: (2017)

DIPG-32. AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Jackson, Evangeline R, et al.
Publicado: (2020)

Diffuse leptomeningeal glioneuronal tumour (DLGNT) in children: the emerging role of genomic analysis
por: Manoharan, Neevika, et al.
Publicado: (2021)

Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
por: Marcrom, Samuel, et al.
Publicado: (2017)

Pembrolizumab After Carbon Ion Radiation Therapy for Alveolar Soft Part Sarcoma Shows a Remarkable Abscopal Effect: A Case Report
por: Okamoto, Masahiko, et al.
Publicado: (2022)

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
por: Schöffski, Patrick, et al.
Publicado: (2023)

Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network
por: Smrke, A., et al.
Publicado: (2022)

The role of radiotherapy in the management of localized soft tissue sarcomas
por: Tiong, Siaw Sze, et al.
Publicado: (2016)

Soft-tissue Sarcomas
por: Vodanovich, Domagoj Ante, et al.
Publicado: (2018)

Metabolic response as assessed by (18)F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
por: Harrison, Douglas J., et al.
Publicado: (2020)

Targeting lipid metabolism in metastatic prostate cancer
por: Scheinberg, Tahlia, et al.
Publicado: (2023)

Application of PD-L1 blockade in refractory histiocytic sarcoma: A case report
por: Imataki, Osamu, et al.
Publicado: (2022)

Processes and Outcomes of Care for Soft Tissue Sarcoma of the Extremities
por: Paszat, Lawrence, et al.
Publicado: (2002)

Neuroblastoma Molecular Risk-Stratification of DNA Copy Number and ALK Genotyping via Cell-Free Circulating Tumor DNA Profiling
por: Kahana-Edwin, Smadar, et al.
Publicado: (2021)

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
por: Ayers, Mark, et al.
Publicado: (2015)

Cutaneous presentation of gastrointestinal adenocarcinoma
por: Halder, Aditi, et al.
Publicado: (2017)

Molecular profiling of childhood cancer: Biomarkers and novel therapies
por: Saletta, Federica, et al.
Publicado: (2014)

Retroperitoneal soft tissue sarcoma
por: Zepeda, Ernesto, et al.
Publicado: (2007)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Soft Tissue Sarcomas of the Kidney
por: Köhle, Olivia, et al.
Publicado: (2015)

Case of Soft Sarcoma of the Cerebellum
por: Steven, James
Publicado: (1870)

Bone and Soft Tissue Sarcoma
por: Ruggiero, Antonio
Publicado: (2020)

Trabectedin for soft tissue sarcoma
Publicado: (2021)

Oxidative stress and antioxidant status in primary bone and soft tissue sarcoma
por: Nathan, Fatima M, et al.
Publicado: (2011)

Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2021)

Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
por: Kim, Chan, et al.
Publicado: (2016)

Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas
por: Kelany, Mohamed, et al.
Publicado: (2021)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma
por: Zanwar, Saurabh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cdk8tt08llf3kapheblc8gpit7